# Pierre Laurent‐Puig

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pierre-laurent-puig/

## Facts

| Field | Value |
| --- | --- |
| Citations | 71,033 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 110 |
| i10-index | 422 |
| OpenAlex ID | https://openalex.org/A5089818289 |
| ORCID iD | https://orcid.org/0000-0001-8475-5459 |
| Works | 1,188 |

## Researcher papers

- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Large-scale genotyping identifies 41 new loci associated with breast cancer risk](https://scholariq.org/papers/large-scale-genotyping-identifies-41-new-loci-associated-with-breast-cancer-risk/)
- [Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability](https://scholariq.org/papers/integrative-analyses-of-colorectal-cancer-show-immunoscore-is-a-stronger/)
- [Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features](https://scholariq.org/papers/stratification-of-pancreatic-ductal-adenocarcinomas-based-on-tumor-and/)
- [Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients](https://scholariq.org/papers/multiplex-picodroplet-digital-pcr-to-detect-kras-mutations-in-circulating-dna/)
- [Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab](https://scholariq.org/papers/amphiregulin-and-epiregulin-mrna-expression-in-primary-tumors-predicts-outcome/)
- [<i>TP53, STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma](https://scholariq.org/papers/i-tp53-stk11-i-and-i-egfr-i-mutations-predict-tumor-immune-profile-and-the/)
- [Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers](https://scholariq.org/papers/mutations-in-the-ras-mapk-pi-3-k-phosphatidylinositol-3-oh-kinase-signaling/)
- [Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis](https://scholariq.org/papers/detection-of-free-circulating-tumor-associated-dna-in-plasma-of-colorectal/)
- [Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial](https://scholariq.org/papers/oxaliplatin-fluorouracil-and-leucovorin-with-or-without-cetuximab-in-patients/)
- [Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)](https://scholariq.org/papers/early-evaluation-of-circulating-tumor-dna-as-marker-of-therapeutic-efficacy-in/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.